Howard Sandler, MD

Chair, Radiation Oncology

Email:howard.sandler@cshs.org
Phone:(310) 423-4234
Fax:(310) 423-6161

Academic Appointments

Professor, Radiation Oncology

Awards and Activities

Ronald H. Bloom Chair in Cancer Therapeutics2009
Program Chair, 2010 ASCO-ASTRO-SUO Genitourinary Cancer Symposium2008
Chairman, RTOG Genitourinary Cancer Committee1997
Editor: Editorial Board, Journal of Clinical OncologyCurrent
Editor: Editorial Board, Journal of Clinical Oncology1994 - 1997

Research Focus

Principal investigator for a national Radiation Therapy Oncology Group study examining radiotherapy and chemotherapy for prostate cancer. Recently led a clinical trial grant funded by the NIH to investigate novel radiation targeting strategies for prostate cancer. Studies also include evaluating the quality of life of prostate cancer patients following surgery and radiation therapy.

Selected Publications

  1. Sandler HM, Liu PY, Dunn RL, Khan DC, Tropper SE, Sanda MG, Mantz CA: Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic Tracking: Assessing the Impact of Margin Reduction Study. Urology, , 2010
  2. Rosenthal SA, Sandler HM, Medscape: Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol, 7(1): 31-8, 2010
  3. Sandler HM, Mirhadi AJ: Radical radiotherapy for prostate cancer is the 'only way to go'. Oncology (Williston Park, N.Y.), 23(10): 840-3, 2009
  4. Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM: The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02. Clin. Cancer Res., 15(17): 5478-84, 2009
  5. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM: Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J. Clin. Oncol., 27(25): 4055-61, 2009
  6. Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM: Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J. Natl. Cancer Inst., 101(4): 228-36, 2009